Pharmaceuticals
Merck reported a net loss in Q2 FY2026 due to a $5.7 billion acquisition charge, even as revenue grew 5% to $16.6 billion driven by Keytruda and Winrevair.
Key risk: U.S. Drug Pricing Legislation Risk
The Inflation Reduction Act and the MFN Agreement impose direct government price setting for key drugs, including Januvia and potentially Keytruda, which could materially reduce revenue and margins.
Other Pharmaceuticals companies